Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Arcellx

Explore full profile

Intelligent and adaptive cell therapies to treat the complexity of human disease

Gaithersburg, United StatesFounded 2015Biotech & Life Sciences
Valuation $6.33B Market cap · 2026
Revenue $22M Latest reported FY

About Arcellx

Arcellx is a clinical-stage biotechnology company focused on developing innovative immunotherapies to transform cell therapy. The company operates in the biopharmaceutical sector, targeting diseases that can be treated through advanced cell therapy techniques. Arcellx's primary clients include healthcare providers, research institutions, and patients in need of cutting-edge treatments for serious conditions. The business model revolves around the research, development, and commercialization of proprietary immunotherapy products. Revenue is generated through partnerships, licensing agreements, and eventual product sales upon regulatory approval. Arcellx aims to address unmet medical needs by leveraging its expertise in cell therapy to create effective and safe treatment options.

Source: Dealroom company data

At a glance

Status
Listed
Founded
2015
Headquarters
Gaithersburg, United States
Listing
IPO 2022
Sector
Biotech & Life Sciences
Power Law
Unicorn$1–10B valuation tierThoroughbred$100M+ revenue

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Investors

23 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A11 investors entered at this stage

  • NEA
  • Novo Ventures
  • Aju IB Investment
  • Quan Capital
  • Takeda Ventures
  • Clough Capital Partners
  • Mirae Asset Capital
  • SR One
  • Mirae Asset Venture Investment
  • Novo Holdings
  • LG Technology Ventures

Series B and later12 investors entered at this stage

  • Samsara BioCapital
  • CAM Capital
  • Soleus Capital
  • Terra Magnum Capital Partners
  • Sixty Degree Capital
  • Cambrian BioPharma
  • CaaS Capital Management
  • Surveyor Capital
  • Adage Capital
  • Suvretta Capital Management
  • Asymmetry
  • Kite Pharma

Talent

Book a demo to see the people
Team profiled 11 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 5 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown
Web traffic by country
4.9K monthly visits
across markets
🇺🇸 United States67.3%
🇮🇳 India16.3%
🇬🇧 United Kingdom14.3%
Top 3 markets shown

Patents

Estimated portfolio value
$14M

9 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Arcellx on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Arcellx on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles